Peer Reviewers and Consultants

Peer Reviewers:

Peer Reviewer	Affiliation	PharmGenEd™ Module
David N. Bailey, M.D	University of California, San Diego	(1) Toxicogenomics
Keola K. Beale, M.D.	University of California, San Diego	(1) Module I ; (2) Module II
Dorit S. Berlin, Ph.D.	Stanford University	(1) Module I ; (2) Module II
Brookie M. Best, Pharm.D., M.A.S.	University of California, San Diego	(1) HIV/AIDS
Shanna A. Block, Pharm.D., BCOP	University of California, San Diego	(1) Module I ; (2) Module II
Daniel A. Brazeau, Ph.D.	University at Buffalo	(1) Module I ; (2) Module II
Coleman J. Bryan Jr., M.D., MSPH	Naval Medical Center, San Diego	(1) Module I ; (2) Module II
Lenny L. Chan, Pharm.D.	Dept. of Public Health, San Francisco	(1) Module I ; (2) Module II
Richard F. Clark, M.D.	University of California, San Diego	(1) Toxicogenomics

Peer Reviewer	Affiliation	PharmGenEd™ Module
Elvan C. Daniels, M.D., M.P.H.	Morehouse School Of Medicine	(1) Module I ; (2) Module II
Willie L. Davis, Ph.D.	Loma Linda University	(1) Module I ; (2) Module II
W. Gregory Feero, M.D., Ph.D.	National Institutes of Health	(1) Module I ; (2) Module II
Alice Gardner, Ph.D.	Massachusetts College of Pharmacy and Health Sciences	(1) Module I ; (2) Module II
James S. Green, Pharm.D., M.B.A., MSEd	Shenandoah University	(1) Module I ; (2) Module II
Gloria R. Grice, Pharm.D., BCPS	St. Louis College of Pharmacy	(1) Module I ; (2) Module II
Cindy Gustafson-Brown, Ph.D.	University of California, San Diego	(1) HIV/AIDS; (2) Toxicogenomics
Arthur F. Harralson, Pharm.D., BCPS	Shenandoah & George Washington Universities	(1) Module I ; (2) Module II
Jan D. Hirsch, Ph.D.	University of California, San Diego	Economic Issues
Laura M. Hodges,	Stanford University	(1) Module I ; (2) Module II

Peer Reviewer	Affiliation	PharmGenEd™ Module
Ph.D.		
Scott Johns, Pharm.D., BCPS(ID)	VASDHS	(1) HIV/AIDS
Julie C. Kissack, Pharm.D., BCPP	Harding University	(1) Module I ; (2) Module II
Grace M. Kuo, Pharm.D., M.P.H., Ph.D.	University of California, San Diego	(1) Asthma; (2) Cardiology I; (3) Cardiology II; (4) Economic Issues; (5) Oncology I; (6) Oncology II; (7) Psychiatry I; (8) Psychiatry II; (9) HIV/AIDS; (10) Toxicogenomics; (11) Diabetes
Jennifer Le, Pharm.D., BCPS-ID	University of California, San Diego	Asthma
Kelly C. Lee, Pharm.D., BCPP	University of California, San Diego	(1) Economic Issues; (2) Oncology I; (3) Oncology II; (4) Psychiatry I; (5) Psychiatry II; (6) Toxicogenomics
Howard P. Levy, M.D., Ph.D.	John Hopkins University	(1) Module I ; (2) Module II
Joseph D. Ma, Pharm.D.	University of California, San Diego	(1) Asthma; (2) Cardiology I; (3) Cardiology II; (4) Economic Issues; (5) Oncology I; (6) Oncology II; (7) Psychiatry II
Sarah McBane, Pharm.D., CDE, BCPS	University of California, San Diego	(1) Asthma; (2) Cardiology I; (3) Cardiology II; (4) Psychiatry I; (5) Diabetes

Peer Reviewer	Affiliation	PharmGenEd™ Module
Gita Mehta, M.D., FACP	University of California, San Diego	(1) Module I ; (2) Module II
Margaret Mendes, Pharm.D.	VA San Diego Healthcare System	(1) Module I ; (2) Module II
Anne N. Nafziger, M.D., Ph.D., M.H.S.	Bertino Consulting	(1) Module I ; (2) Module II
Wilson D. Pace, M.D.	University of Colorado Denver	(1) Module I ; (2) Module II
Nathan Painter, Pharm.D., CDE	University of California, San Diego	(1) Diabetes
Mary W. Roederer, Pharm.D., CPP, BCPS	University of North Carolina	(1) Module I ; (2) Module II; (3) Diabetes
Katrin Sangkuhl, Ph.D.	Stanford University	(1) HIV/AIDS
Jaekyu Shin, Pharm.D., M.S., BCPS	University of California San Francisco	(1) Module I ; (2) Module II
Caroline Tsai, Pharm.D., BCPP	San Francisco General Hospital	(1) Module I ; (2) Module II
Marc S. Williams, M.D., FAAP,	Intermountain	(1) Module I ; (2) Module II

Peer Reviewer	Affiliation	PharmGenEd™ Module
FACMG	Healthcare	
Christopher A. Woo, Pharm.D.	Walgreens	(1) Module I ; (2) Module II
Chen Xu, Ph.D., R.Ph.	Consultant	(1) Module I ; (2) Module II

The contents presented in the continuing education (CE) modules (Module I and Module II) and specific therapeutic area modules are solely the responsibility of the authors/presenters and do not necessarily represent the individual views of peer reviewers.

Consultants:

Karen S. Hudmon, Dr.P.H., M.S., R.Ph., Professor of Pharmacy Practice at Purdue University College of Pharmacy Department of Pharmacy Practice, has assisted the PharmGenEd program by evaluating curriculum delivery methods and the effectiveness of targeting different audience groups. Her research involves (1) the study of predictors of smoking among adolescents and young adults; (2) the treatment of tobacco use and dependence through expansion of the clinician's role in cessation; (3) understanding genetics as they relate to tobacco use and dependence; and (4) medication compliance for chronic disease. She has co-coordinated an effort to develop, evaluate, and disseminate a comprehensive tobacco cessation training program, Rx for Change: Clinician-Assisted Tobacco Cessation, for students in the health professions. This program is being disseminated to health professional schools across the US and has witnessed broadscale adoption.

Magnus Ingelman-Sundberg, Ph.D. was involved in the development of the education curriculum focusing on pharmacogenomics primer concepts and clinical applications in concentrated therapeutic areas. He is a Professor of Physiology and Pharmacology, and Head of the Section of Pharmacogenetics at the Karolinska Institute in Sweden. He is the Chairman of the Editorial Board for Pharmacogenetics and Genomics. In 2008 he was named to the Nobel Assembly. Dr. Ingelman-Sundberg's research has focused on the function, regulation, and pharmacogenetics of CYP. He has emerged as a leading scientist in characterizing novel CYP polymorphisms and elucidating their clinical significance. Among his pioneering findings is the importance of CYP2D6 gene duplications in causing an ultrarapid metabolizer phenotype that renders patients non-responsive to antidepressants and prone to adverse effects of codeine. His laboratory is currently pursuing genetic as well as epigenetic reasons for interindividual

variability CYP3A4 and CYP1A2 expression. His group identified new extrahepatic CYPs that are overexpressed in certain cancer cells and may prove to be novel drug targets.